You are here

Prospective Evaluation of the Radiographic Efficacy of Enbrel

Last updated on July 31, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis, Psoriasis Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject eligibility should be reviewed and documented by an appropriately qualified
member of the investigator's study team before subjects are included in the study.

- Evidence of a personally signed and dated informed consent document indicating that
the subject (or a legally acceptable representative) has been informed of all
pertinent aspects of the study is a requirement for inclusion into this study.

Subjects must meet all of the following inclusion criteria to be eligible for enrollment
into the study:

- Subjects who are willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.

- Definitive diagnosis of RA or PsA.

- Eligible for Etanercept treatment according to Summary of Product Characteristics
(SmPC).

- Inclusion of subjects pretreated with other biologics other than Etanercept is
possible

- One plain radiograph of hands and feet (Anteroposterior) within 3 month prior to
initiation of treatment with Etanercept and one planned consecutive radiograph of hand
and feet taken over 12 to 18 months according to German recommendations for patients
treated with biologics.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Receipt of any investigational drug within 3 months of study inclusion.

- Exclusion Criteria according to the Enbrel® SmPC, with particular attention to:

- Hypersensitivity to the active substance (etanercept) or to any of the excipients.

- Sepsis or risk of sepsis.

- Active infections, including chronic or localised infections.

- Subjects who have received any previous treatment with etanercept

- Subjects who are investigational site staff members or subjects who are Pfizer
employees directly involved in the conduct of the trial.

NCT01623752
Pfizer
Enrolling by invitation
Prospective Evaluation of the Radiographic Efficacy of Enbrel

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Prospective Evaluation of the Radiographic Efficacy of Enbrel
A Prospective Evaluation Of The Radiographic Efficacy Of Etanercept In Patients With Rheumatoid Arthritis Or Psoriatic Arthritis.

It is known from the COMET-trial that patients who start Enbrel treatment early have a great chance of reaching clinical remission and radiographic nonprogression. It is still unclear, however, how many patients with early arthritis achieve remission and radiographic nonprogression under the conditions of routine rheumatologic care and the local recommendations of Enbrel treatment (pre-treatment of at least 2 DMARDs, one of them MTX).

Therefore, no robust x-ray data are available to show/demonstrate

  • the average extent of x-ray damage in routine patients on Enbrel outside clinical studies.
  • if the outstanding effect on structural damage of Enbrel can be reproduced in routine practice.
  • that the 'Silent Progressor' is an issue relevant not only in clinical trials, but also for day-to-day decision making.
  • the optimal onset of Enbrel treatment in the course of the disease to prevent radiographic damage
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Only patients for whom the decision has already been made to initiate treatment with Enbrel® can be enrolled in this observational trial. These patients must have a proven diagnosis of Rheumatoid Arthritis or Psoriasis Arthritis
  • Rheumatoid Arthritis
  • Psoriasis Arthritis
Drug: Etanercept
The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Other Name: Enbrel
  • Patients with Rheumatoid Arthritis
    Intervention: Drug: Etanercept
  • Patients with Psoriasis Arthritis
    Intervention: Drug: Etanercept
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
2000
April 28, 2018
April 28, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator's study team before subjects are included in the study.
  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study is a requirement for inclusion into this study.

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Definitive diagnosis of RA or PsA.
  • Eligible for Etanercept treatment according to Summary of Product Characteristics (SmPC).
  • Inclusion of subjects pretreated with other biologics other than Etanercept is possible
  • One plain radiograph of hands and feet (Anteroposterior) within 3 month prior to initiation of treatment with Etanercept and one planned consecutive radiograph of hand and feet taken over 12 to 18 months according to German recommendations for patients treated with biologics.

Exclusion Criteria:

  • Receipt of any investigational drug within 3 months of study inclusion.
  • Exclusion Criteria according to the Enbrel® SmPC, with particular attention to:
  • Hypersensitivity to the active substance (etanercept) or to any of the excipients.
  • Sepsis or risk of sepsis.
  • Active infections, including chronic or localised infections.
  • Subjects who have received any previous treatment with etanercept
  • Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01623752
B1801317
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now